Navigation Links
Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
Date:10/17/2007

m health

"Educating the patient community and sharing scientific knowledge with healthcare professionals, such as transplant nurses, is Astellas' responsibility as a leader in the field of transplantation," said M. Roy First, M.D., Vice President, Global Immunology, Astellas Pharma US, Inc. "This partnership further strengthens our relationship with the transplant community and provides vital information to patients and caregivers about the transplant experience."

The first piece developed jointly by ITNS and Astellas is a brochure, "Kidney Function and Your New Organ," available both in a hard copy format, and a downloadable version through http://www.TransplantExperience.com.

About ITNS

The International Transplant Nurses Society was founded in 1992 as the first professional nursing organization to promote the education and clinical practice excellence of nurses caring for solid organ transplant patients. Today, ITNS is a leading transplant organization with more than 1,400 active members representing 29 countries around the world.

A vital component of countless nursing careers, ITNS provides a forum for learning about the most current advances in transplantation and transplant patient care. Over the years ITNS has provided skilled transplant nurses the opportunity to share and learn with national and international peers and to receive recognition for their knowledge, leadership, and scholarly pursuits.

About Astellas

Astellas is a recognized leader in transplantation and has been committed to the field of immunology for more than 20 years. Dedicated to supporting the advancement of care for patients, Astellas continues to build upon its legacy and leadership in transplantation by investing in ongoing clinical research and new product development.

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
(Date:6/1/2015)... and YONGIN, South Korea ... great pride that Green Cross Biotherapeutics Inc. (GCBT) kicked ... be located on the Montreal Technoparc,s Saint-Laurent Campus. The ... field investment projects in Canada ... of the first intravenous immunoglobulin (IVIG) and albumin manufacturing ...
(Date:6/1/2015)... , June 1, 2015 ... Decipher® genomic analysis platform, successfully classified various ... genomic expression of certain biomarkers, including one ... Importantly, this unique genomic signature has potential ... to neoadjuvant chemotherapy in patients with muscle-invasive ...
(Date:6/1/2015)... Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results for ... first quarter financial statements and MD&A have been filed on SEDAR ... 31,(in CDN$,000 except per share data) , 2015 , ... profit , 1,531 , 329 Ebitda* , ... , (531) Basic earnings (loss) per share ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
... in reconstructive and aesthetic plastic surgeryMEDFORD, Mass., ... growth-stage medical device company developing silk-based biomaterial ... has received 510(k) clearance from the U.S. ... SeriScaffold (TM) silk-based, long term bioresorbable ...
... /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine ... the National Institute of Allergy and Infectious Diseases ... in Maryland, USA. The research collaboration involves formulating ... and exploring potential vaccines for HIV and malaria. ...
... its financial results for the year ending 31,December 2008. , , ... process for intravenous iclaprim in US, - Restructuring ... "intravenous-to-oral" Phase II trial with oral, ... - Share placing, Cash and financial investments of CHF ...
Cached Biology Technology:Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 3Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 4ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria 2Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Genetic disease risk differences between one individual and another are ... the genes themselves, or else differences at the heart of ... By gene regulation we mean the decision that the cell ... activate or suppress the expression of a gene. In theory, ...
... those with HIV have recognized a relationship between how faithfully ... virus is to develop drug resistance. More recently, research has ... and resistance is different for each of the drugs that ... New research conducted by Harvard scientists could help explain ...
... ARBOR, Mich. Scientists have restored the sense of smell ... a hopeful sign for people who can,t smell anything from ... in curing congenital anosmia -- the medical term for lifelong ... other conditions that also stem from problems with the cilia. ...
Cached Biology News:A new light shed on genetic regulation's role in the predisposition to common diseases 2Design help for drug cocktails 2Design help for drug cocktails 3Can't smell anything? This discovery may give you hope 2Can't smell anything? This discovery may give you hope 3
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Request Info...
Biology Products: